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Abstract
Background: Black women living in southern states have the highest breast cancer mortality rate in the United States. The
prognosis of de novo metastatic breast cancer is poor. Given these mortality rates, we are the first to link nationally
representative data on breast cancer mortality hot spots (counties with high breast cancer mortality rates) with cancer
mortality data in the United States and investigate the association of geographic breast cancer mortality hot spots with de
novo metastatic breast cancer mortality among Black women. Methods: We identified 7292 Black women diagnosed with de
novo metastatic breast cancer in Surveillance, Epidemiology, and End Results (SEER). The county-level characteristics were
obtained from 2014 County Health Rankings and linked to SEER. We used Cox proportional hazards models to calculate ad-
justed hazard ratios (aHRs) and 95% confidence intervals (CIs) for mortality between hot spot and non–hot spot counties.
Results: Among 7292 patients, 393 (5.4%) resided in breast cancer mortality hot spots. Women residing in hot spots had
similar risks of breast cancer–specific mortality (aHR ¼ 0.99, 95% CI ¼ 0.85 to 1.15) and all-cause mortality (aHR ¼ 0.97, 95% CI
¼ 0.84 to 1.11) as women in non–hot spots after adjusting for individual and tumor-level factors and treatments. Additional
adjustment for county-level characteristics did not impact mortality. Conclusion: Living in a breast cancer mortality hot spot
was not associated with de novo metastatic breast cancer mortality among Black women. Future research should begin to
examine variation in both individual and population-level determinants, as well as in molecular and genetic determinants
that underlie the aggressive nature of de novo metastatic breast cancer.
Breast cancer is the most common cancer among women in the
United States, with the highest incidence in White women. Yet,
racial and ethnic disparities in breast cancer mortality rates per-
sist (1,2). In the most recent period (2013-2017), the breast can-
cer mortality rate was 40% higher in Black women (28.4 per
100 000) vs White women (20.3 per 100 000) (2). Across all racial
and ethnic groups, the stage of diagnosis is associated with sur-
vival. For women diagnosed with American Joint Committee on
Cancer (AJCC)–defined stage I breast cancer, the expected 5-year
breast cancer–specific survival rate is more than 96% (2).
However, 5-year breast cancer–specific survival rates decrease
as patients are diagnosed beyond AJCC stage I (3).
Approximately 5%-10% of all new breast cancer diagnoses
are AJCC stage IV, also called de novo metastatic breast cancer
(4,5). The overall prognosis for de novo metastatic breast cancer
is poor, with the median overall survival ranging from 19 to
28 months (5,6); however, there have been recent improvements
(4). These improvements may be partly attributed to advances
in the molecular-level characterizations of breast cancer, use of
hormone therapy, and targeted treatment strategies (7). Despite
these improvements, breast cancer survival remains low among
Black patients in late-stage distant metastatic breast cancer,
according to The American Cancer Society’s "Breast Cancer
Facts and Figures 2019-2020” (8).
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As seen across racial and ethnic groups, geographic dispar-
ities in breast cancer outcomes exist across the United States
(9). Historical factors, such as Jim Crow laws, housing and zon-
ing policies, and migration patterns, have created swaths of ra-
cially segregated areas that still exist today (10,11). There has
been an emergence of interdisciplinary researchers interested
in the intersection of race and geographical location on health
outcomes. Disease-specific geographic hot spots are the spatial
aggregation of cases in an identifiable subpopulation based on
geographic excess risks (12). A breast cancer mortality hot spot
is a county identified as high risk for breast cancer mortality.
Hot spots of breast cancer mortality among Black women were
found primarily in rural southern counties near the Mississippi
River and counties in the northern coastal North Carolina and
southern Virginia areas of the United States (13).
However, to our knowledge, no study has investigated asso-
ciations between geographic hot spots and mortality among
Black women with de novo metastatic breast cancer. Thus, we
are the first to link nationally representative data on breast can-
cer mortality hot spots with incident-based mortality data on
de novo metastatic breast cancer in the United States and ex-
amine the association of geographic breast cancer mortality hot
spots with de novo metastatic breast cancer mortality among
Black women. Understanding this association can help medical
and public health experts tailor programs and maximize resour-
ces to improve survivorship rates for this vulnerable group.
Methods
Study Design and Data
Data for this study were obtained from the Surveillance,
Epidemiology, and End Results (SEER) 18 Registries Custom Data
and the Centers for Disease Control and Prevention’s underlying
causes of death file (14,15). This study was considered exempt
by the institutional review board of Washington University
School of Medicine because we used existing secondary data
that are publicly available and nonidentifiable.
Study Population
We used “case listing” function through SEER*Stat software (ver-
sion 8.3.6) to export potential cases for analysis from the SEER
18 database (16). Female patients with known age and diag-
nosed with first primary breast cancer from 1990 to 2016 were
potentially eligible for this study (n¼ 1 007 821; Figure 1).
Women were excluded if they had no distant metastases or un-
known metastatic information (n¼ 959 191); lacked microscopic
confirmation (n¼ 2369); were without active follow-up (n¼ 65);
lived in Alaska, Hawaii, or unknown hot spot counties (n¼ 843);
were not non-Hispanic Blacks (hereinafter, Blacks) (n¼ 38 061).
Thus, our sample consisted of 7292 Black women with de novo
metastatic breast cancer for final analysis. Individual demo-
graphic and clinical characteristics in SEER were used as poten-
tial covariates including age at diagnosis, year of diagnosis,
marital status, tumor histology, tumor grade, hormone receptor
status, the first course of treatments (surgery, radiation, and
chemotherapy), and SEER registry. In brief, patients in metro
counties with codes 1-3 were classified as urban, and all non-
metro counties with codes 4-9 were classified as rural.
Hot Spots of Breast Cancer Mortality Among Black
Women
Although a variety of approaches exist for spatial disease clus-
tering, we used the aggregation of 3 separate local and global
spatial clustering methods to identify counties that were hot
spots for breast cancer mortality. This cluster identification
method has been described in detail previously (13,17,18), and
the use of this conservative approach helps avoid spurious
results obtained from simply relying on one method. Briefly, we
categorized county-level breast cancer mortality into 2 groups—
hot spots or non–hot spots—based on a statistically significant
higher observed vs expected breast cancer mortality rate. Hot
spot counties are those identified as high risk for breast cancer
mortality using all 3 approaches: 1) fifth quintile of smoothed
Empirical Bayes breast cancer mortality rates, 2) high-high clus-
ters using local indicators of spatial association, and 3) as a hot
spot defined by Getis-Ord Gi* statistic (19,20). All other contigu-
ous US counties were categorized as non–hot spots.
County-Level Characteristics
To obtain characteristics on county-level demographic, socio-
economic, and health availability and/or community resources,
cases identified in SEER were linked with county-level data
1,007,821 female patients with known age, 
first primary breast cancer diagnosed from 
1990 to 2016 in SEER 18 registries 
 1,000,529 Excluded 
959,191 No distant metastases or unknown 
metastatic information 
2,369 Not microscopic confirmed 
65 Not active follow-up 
843 Women living in Alaska and Hawaii, 
and unknown hot spot counties 
38,061 Not non-Hispanic Blacks 
7,292 Eligible patients for final analysis 
Figure 1. Flowchart of eligible individuals, SEER 18 registries 1990-2016. SEER ¼ Surveillance, Epidemiology, and End Results.
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from the 2014 County Health Rankings (CHR) and the 2014
American Community Survey (ACS) based on county Federal
Information Processing Standards codes (21). The CHR and ACS
comprise nationally representative data collected from a sam-
ple of the total noninstitutionalized population aged 18 years
and older residing in households. The CHR database uses sev-
eral survey samples to provide generalizable estimates of
county-level factors, and the ACS provides aggregated estimates
for demographic statistics over 5 years (2014 ACS, years 2010-
2014). From CHR and ACS, we considered estimates of the
county-level proportions of race and ethnicity, completed col-
lege, household income, obesity, smoking, excessive drinking,
persons who could not see a doctor because of costs, limited ac-
cess to healthy foods, mammography screening, physical inac-
tivity, access to exercise opportunities, unemployment,
uninsured, the ratio of primary care physicians per 100 000 per-
sons, and rurality. County-level rurality was evaluated as a di-
chotomous variable (rural-urban) using 2010 Rural-Urban
Commuting Area classifications, where urban areas were de-
fined as population centers with more than 50 000þ residents,
and rural and nonurban areas were defined as towns or small
cities with population centers with fewer than 50 000 residents.
Statistical Analysis
We compared bivariate differences in participant and tumor
characteristics, county-level characteristics, and survival time
in hot spots vs non–hot spot counties using v2, analysis of vari-
ance, or Wilcoxon rank-sum tests as appropriate. We compared
hot spots vs non–hot spot counties and presented the medians
and interquartile ranges for the county-level characteristics be-
cause of the nonparametric distribution of continuous variables
(Table 2). Because of the large number of counties examined,
there were many associations considered statistically signifi-
cant at a equals 0.05. Therefore, to observe the magnitude of the
correlation between hot spots and county-level characteristics,
we additionally examined the correlation of county-level char-
acteristics with residents at diagnosis in county-level hot spots
of breast cancer mortality using a Spearman correlation (q, posi-
tive values indicate positive correlation, and negative values in-
dicate negative correlation). We examined the proportional
hazards assumption for breast cancer–specific survival and
overall survival by Schoenfeld residuals and by graphically
assessing the log-log plots of survival. Therefore, we used Cox
proportional hazards models to assess hazard ratios (HR) and
95% confidence intervals (CIs) for time to death from de novo
metastatic breast cancer comparing hot spot and non–hot spot
residence. Survival time was estimated from the date of diagno-
sis to the last date of follow-up or death. We performed a se-
quential model-building approach to examine possible
confounders on the association between hot spot residence and
mortality. The contribution of individual-level covariates, tumor
factors, and treatments for multivariable models was assessed
by a measure of the relative change in hazard ratios (22).
Multivariable-adjusted model 1 was adjusted for individual-
level factors (age, year of diagnosis, marital status, and SEER
registries), tumor-level factors (tumor histology, tumor grade,
and hormone receptor status), and treatments (surgery, chemo-
therapy, and radiation therapy). Multivariable-adjusted model 2
was adjusted for all factors in multivariable-adjusted model 1
with additional county-level factors that were associated with
hot spots in a moderate Spearmen correlation (q j0.20j). We
performed statistical analyses using SAS version 9.4. All




Among 7292 Black women diagnosed with de novo metastatic
breast cancer over the 27-year study period, approximately 5.4%
(n¼ 393) women resided in hot spot counties at their diagnosis
(Table 1). The mean age of all patients was 58.47 years and did
not statistically significantly differ by hot spot classification
(Table 1). Compared with women living in non–hot spot coun-
ties, women residing in hot spot counties were more likely to be
diagnosed between 2010 and 2016 (52.9% vs 40.8%), more likely
to reside in rural areas (18.3% vs 6.1%), more likely to have duc-
tal histology of breast tumor (73.5% vs 67.7%), and more likely to
have grade 2 tumor (30.5% vs 23.1%) (Table 1).
County-level characteristics by hot spot classification are
presented in Table 2. Black women living in hot spot counties
with de novo metastatic breast cancer diagnosis were statisti-
cally significantly more likely than women living in non–hot
spot counties to reside in areas with greater proportions of
White residents (59.3% vs 46.6%), a greater prevalence of adult
obesity (33.5% vs 26.9%), a greater prevalence of smoking (20.8%
vs 14.8%), more physical inactivity (32.0% vs 24.1%), and a
greater proportion of rural residents (13.2% vs 1.1%). Moreover,
hot spot counties were statistically significantly less likely than
non–hot spot counties to have greater proportions of Hispanic
(5.0% vs 9.1%), to be areas with college completion rates (22.8%
vs 29.9%), to have access to exercise opportunity (57.1% vs
92.5%), and less unemployment (7.5% vs 9.6%).
Hot Spot Residence and Mortality
Over a median of 14 months, 5995 women (82.2%) died, includ-
ing 5363 women (73.5%) from breast cancer (Table 3). Patients
who resided in a breast cancer mortality hot spot were not at in-
creased risk of death from de novo metastatic breast cancer
mortality (adjusted hazard ratios [aHR] ¼ 0.99, 95% CI ¼ 0.86 to
1.13) compared with women living in non–hot spot counties,
while controlling for individual-level factors, tumor-level fac-
tors, and treatments in multivariable model 1 (Table 3). We ob-
served similar results after additionally adjusting for county-
level proportions, including completed college education, popu-
lation with obesity, current smoking status, physically inactive,
and access to exercise opportunities, in multivariable model 2.
Similarly, in fully adjusted models, women residing in hot spots
had similar risks of breast cancer–specific mortality (aHR ¼ 0.99,
95% CI ¼ 0.85 to 1.15) and all-cause mortality (aHR ¼ 0.97, 95% CI
¼ 0.84 to 1.11) as women in non–hot spots after adjusting for in-
dividual and tumor-level factors and treatments (Table 3).
Furthermore, the lack of association persisted when we evalu-
ated different segments of follow-up time after disease diagno-
sis using piecewise Cox proportional hazards model controlling
for full covariates in model 2 (0-2 years aHR ¼ 1.05, 95% CI ¼ 0.90
to 1.22; 2-4 years aHR ¼ 1.20, 95% CI ¼ 0.90 to 1.61; 4-6 years aHR
¼ 1.23, 95% CI ¼ 0.74 to 2.03; 6 years aHR ¼ 0.95, 95% CI ¼ 0.43
to 2.10; data not shown). Individual-level factors reduced the
hazard ratio by 3.2%, treatments reduced the hazard ratio by
4.2%, and county-level factors reduced the hazard ratio by 1.6%,
whereas tumor-level factors increased the hazard ratio by 2.7%.
In total, adjustment for all covariates explained 6.2% of the
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breast cancer–specific survival across hot spot classification
(Supplementary Table 2, available online). Additionally, the haz-
ard ratios for overall mortality were similar to findings for
breast cancer–specific mortality (Table 3).
For comparison purposes, we examined the hazard ratios
and 95% confidence intervals for all women in SEER 18 database
from 1990 to 2016 (Supplementary Table 3, available online).
Among 45 353 women, 30 967 were Whites (68.3%), 7292 were
Blacks (16.1%), 4433 were Hispanic (9.8%), and 2661 were other
races (5.9%). For this analysis, we identified 80 of 3108 (2.6%)
counties as hot spots for breast cancer mortality for all women
as our previous published article in mapping hot spots of breast
cancer mortality in the United States (13). Among all women,
we observed that residence in breast cancer mortality hot spots
was not associated with increased risk of de novo metastatic
breast cancer death (aHR ¼ 1.06, 95% CI ¼ 0.91 to 1.24;
Supplementary Table 4, available online) after controlling for
individual-level factors (age, race, marital status, and SEER reg-
istry). Compared with White women, Black women have a 30%
increased risk of breast cancer–specific death (aHR ¼ 1.30, 95%
CI ¼ 1.26 to 1.34; Supplementary Table 4, available online).
Discussion
In this study, we are the first to link nationally representative
data on breast cancer mortality hot spots with incident-based
mortality data on de novo metastatic breast cancer among 7292
Black women in the United States. We observed that Black
Table 1. Comparison of participant and tumor characteristics by breast cancer mortality hot spot classification among 7292 Black women diag-
nosed as de novo metastatic breast cancer from SEER 18 registries, 1990-2016
Characteristics Total (n¼ 7292)
Breast cancer mortality hot spot counties
Hot spota (n¼ 393; 5.4%) Non–hot spot (n¼ 6899; 94.6%) Pb
Age at diagnosis, mean (SE), y 58.47 (0.17) 58.33 (0.72) 58.48 (0.17) .95
Age at diagnosis, No. (%), y
<40 706 (9.7) 39 (9.9) 667 (9.7) .80
40-49 1246 (17.1) 65 (16.5) 1181 (17.1)
50-59 1980 (27.2) 101 (25.7) 1879 (27.2)
60-69 1699 (23.3) 102 (26.0) 1597 (23.2)
70-79 1105 (15.2) 54 (13.7) 1051 (15.2)
80 556 (7.6) 32 (8.1) 524 (7.6)
Year of diagnosis, No. (%)
1990-1999 1011 (13.9) 3 (0.8) 1008 (14.6) <.001
2000-2009 3256 (44.7) 182 (46.3) 3074 (44.6)
2010-2016 3025 (41.5) 208 (52.9) 2817 (40.8)
Survival time, months, mean (SE) 23.72 (0.37) 21.59 (1.34) 23.84 (0.38) .56
Marital status, No. (%)
Single or never married 2582 (35.4) 134 (34.1) 2448 (35.5) .38
Married or domestic partner 1940 (26.6) 100 (25.5) 1840 (26.7)
Divorced, separated, or widowed 2383 (32.7) 131 (33.3) 2252 (32.6)
Unknown 387 (5.3) 28 (7.1) 359 (5.2)
Urban or rural residence, No. (%) <.001
Urban 6801 (93.3) 321 (81.7) 6480 (93.9)
Rural 491 (6.7) 72 (18.3) 419 (6.1)
Tumor histology, No. (%)
Ductal 4960 (68.0) 289 (73.5) 4671 (67.7) .04
Lobular 541 (7.4) 31 (7.9) 510 (7.4)
Mixed ductal and lobular 233 (3.2) 10 (2.5) 223 (3.2)
Other histology 1558 (21.4) 63 (16.0) 1495 (21.7)
Tumor grade, No. (%)
1 (well differentiated) 251 (3.4) 17 (4.3) 234 (3.4) .01
2 (moderately differentiated) 1716 (23.5) 120 (30.5) 1596 (23.1)
3 (poorly differentiated) 3236 (44.4) 159 (40.5) 3077 (44.6)
4 (undifferentiated) 135 (1.9) 7 (1.8) 128 (1.9)
Unknown 1954 (26.8) 90 (22.9) 1864 (27.0)
Hormone receptor status, No. (%)
Positive (ERþ or PRþ) 3913 (53.7) 205 (52.2) 3708 (53.8) .61
Negative (ER- and PR-) 1993 (27.3) 116 (29.5) 1877 (27.2)
Unknown 1386 (19.0) 72 (18.3) 1314 (19.1)
Surgery, No. (%), yes 2541 (34.9) 136 (34.6) 2405 (34.9) .18
Radiation, No. (%), yes 2339 (32.1) 111 (28.2) 2228 (32.3) .09
Chemotherapy, No. (%), yes 4141 (56.8) 224 (57.0) 3917 (56.8) .93
aPatients residing in counties with high breast cancer mortality (fulfilling all 3 criteria for geographic clustering). ER ¼ estrogen receptor; PR ¼ progesterone receptor;
SEER ¼ Surveillance, Epidemiology, and End Results.
bStatistical significance determined using v2 tests for categorical variables, analysis of variance (ANOVA) for parametric continuous variables, or Wilcoxon rank-sum
tests for nonparametric continuous variables.
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women diagnosed with de novo metastatic breast cancer had
similar risk of death regardless of residence in county-level hot
spots of breast cancer mortality.
The incidence of distant-stage breast cancer has increased
over the past few decades (23). This increase may be partly
explained by the more complete staging of advanced tumors
(24) and increased use of advanced imaging to detect asymp-
tomatic metastases (8). The prevalence of metastatic breast
cancer in the United States from 1990 to 2020 was estimated
that there will be 168 292 women living with metastatic breast
cancer by 2020 (25). Evidence indicated that the odds of late-
stage breast cancer among Black women were 43% higher
when compared with their White counterparts (26) and dem-
onstrated a widening racial and ethnic disparity gap in breast
cancer stage at diagnosis in the recent decade (27-31). Further,
studies using SEER data suggested that Black women may
have up to a 45% increased risk of death from HER2-positive
metastatic breast cancers when compared with White women
(32). In comparison, another report of data from 2 breast-
specific practices suggested that race and ethnicity may not
contribute to the survival of patients diagnosed with de novo
metastatic breast cancer (33). Differences in age distribution,
race and ethnicity, comorbidities, and tumor factors could
lead to survival differences between large SEER data and small
practices. These mixed and limited studies support our explo-
ration of breast cancer mortality hot spots and de novo meta-
static breast cancer mortality among Black women, despite
our null findings.
Table 2. County-level characteristics by breast cancer mortality hot spot classification among 7292 Black women from SEER 18 registries, 1990-
2016, linked with 2014 American Community Survey and County Health Rankings county-level data
County-level characteristics
Breast cancer mortality hot spot counties
Hot spota (n¼ 393; 5.4%) Non–hot spot (n¼ 6899; 94.6%)
Pb qcMedian (IQR)d Median (IQR)d
% NH-White 59.3 (55.6-65.9) 46.6 (33.4-55.4) <.001 0.17
% NH-Black 26.0 (18.5-36.6) 24.0 (8.4-40.0) <.001 0.04
% Hispanic 5.0 (1.9-12.8) 9.1 (5.3-22.6) <.001 0.14
% Completed college 22.8 (13.3-25.8) 29.9 (21.7-39.4) <.001 0.21
% Household income <$20,000 20.3 (16.8-26.8) 18.5 (16.0-26.0) <.001 0.08
% Obesity 33.5 (32.0-36.4) 26.9 (22.9-33.6) <.001 0.23
% Smoking 20.8 (19.2-21.1) 14.8 (12.3-20.9) <.001 0.20
% Excessive drinking 14.4 (12.0-17.2) 16.0 (15.0-17.7) <.001 0.05
% Could not see doctor because of cost 16.2 (13.6-17.6) 15.6 (13.5-18.1) <.001 0.07
% Limited access to healthy foodse 5.0 (4.4-11.5) 4.0 (1.6-7.7) <.001 0.16
% Mammography screening 61.4 (57.1-61.8) 59.3 (57.5-62.0) .07 0.02
% Physical inactivity 32.0 (27.8-32.9) 24.1 (19.6-27.7) <.001 0.32
% Access to exercise opportunities 57.1 (40.2-88.8) 92.5 (81.2-96.8) <.001 0.25
% Unemployment 7.5 (6.2-10.6) 9.6 (8.6-10.9) <.001 0.19
% Uninsured 26.6 (19.4-27.9) 24.5 (21.5-28.5) .59 0.01
PCP per 100 000 persons 6.7 (3.8-8.6) 7.1 (6.5-9.4) .42 0.12
% Nonurban (rural) 13.2 (1.6-24.2) 1.1 (0.6-5.9) <.001 0.15
aPatients residing in counties with high breast cancer mortality (fulfilling all 3 criteria for geographic clustering). IQR ¼ interquartile range; NH ¼ non-Hispanic; PCP ¼
primary care physicians; SEER ¼ Surveillance, Epidemiology, and End Results.
bStatistical significance determined using v2 tests for categorical variables or Wilcoxon rank-sum tests for nonparametric continuous variables.
cSpearman correlation with being a county-level breast cancer mortality hot spot.
dMedian and IQR.
eIndex that ranges from 0 (worst) to 10 (best), depending on the access to healthy foods by considering the distance an individual lives from a grocery store or
supermarket.
Table 3. Multivariable hazard ratios for breast cancer–specific mortality and overall mortality among 7292 Black women diagnosis with de
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Non–hot spot 5076/6899 (73.6) Referent Referent Referent 5678/6899 (82.3) Referent Referent Referent












aNumbers presented were from the Black women cohort (n¼ 7292). CI ¼ confidence interval; HR ¼ hazard ratio; SEER ¼ Surveillance, Epidemiology, and End Results.
bModel 1 was adjusted for age at diagnosis, year of diagnosis, marital status, tumor histology, tumor grade, hormone receptor status, treatments (surgery, radiation,
and chemotherapy), and SEER registry.
cModel 2 was additionally adjusted for county-level proportions for completed college education, population with obesity, current smoking status, physically inactive,
and access to exercise opportunities in addition to model 1.
dModel 3 was adjusted for all individual-level, tumor-level, and county-level variables.
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There is limited knowledge on both the geographic and ra-
cial patterns in de novo metastatic breast cancer in the United
States. Several studies suggested an association between race
and/or racial segregation with overall breast cancer outcomes.
For instance, Bemanian and colleagues (34) observed that higher
Black racial segregation was associated with a 9% lower risk of
breast cancer–specific mortality among a sample of 940 Blacks
diagnosed with invasive breast cancer. However, in a recent sys-
tematic review, Landrine and colleagues (35) found that living
in segregated African American communities was associated
with higher odds of late-stage breast cancer. Likewise, Pruitt
and colleagues (36) reported that greater Black segregation was
associated with a twofold increased risk of breast cancer–spe-
cific mortality; however, race and other factors explained away
much of this association, with Black race being associated with
a 46% increased risk of breast cancer mortality. Russell and col-
leagues (37) observed that among women in Georgia, segrega-
tion was associated with a twofold increased risk of death
attributed to breast cancer for Black women, but not among
White women. However, these racial segregation associations
are complex because racial enclaves for Black women may lead
to key survivorship and quality-of-life benefits such as in-
creased social support, more culturally relevant care, more will-
ingness to access care, and less exposure to stress from racism
(34). To this end, because of the limited research surrounding
the association between social determinants of health and de
novo metastatic breast cancer specifically, future studies should
continue to explore the social determinants of this disease and
attempt to provide the geospatial distribution of metastatic
breast cancer among the entire US population, which will pro-
vide insight into the highest areas of need for this increasing
public health concern.
In our findings, we observed that among patients diagnosed
with de novo metastatic breast cancer, there were no differen-
ces in breast cancer survival regardless of patients’ county of
residence, even after adjustment for individual-level, tumor-
level, and county-level variables. This could be due to other
complex biology related to the aggressive phenotype of de novo
metastatic breast cancer. Many cell cycle components contrib-
ute to a more aggressive tumor phenotype and poorer prognosis
among Black breast cancer patients (38), such as higher mitotic
index; overexpression of cyclin E, p16, p53; and lower expres-
sion of cyclin D1 (39). A better understanding of the key molecu-
lar determinants and genetic alterations that underlie clinical
behavior in Black patients may also elucidate the higher mortal-
ity of de novo metastatic breast cancer.
Our study is strengthened by the use of nationally represen-
tative data to define mortality hot spots, as well as survival
follow-up in SEER, which includes clinical and demographic
data. Additionally, we were able to account for individual and
population-level factors through multilevel modeling. However,
the SEER database covers only 16 geographic areas within the
contiguous United States of which only 5 areas (Iowa, New
Mexico, Utah, Rural Georgia, and Kentucky) are considered ru-
ral. Last, SEER lacks data on comorbid conditions, where Black
women were more likely than White women to have higher co-
morbidity scores (32).
Hot spots of breast cancer mortality for Black women were
not associated with de novo metastatic breast cancer mortality.
Our exploration adds to the limited evidence on geographic and
racial patterns in metastatic breast cancer disease and mortality
in Black women. Future research should begin to examine varia-
tion in both individual and population-level determinants, as
well as in molecular and genetic determinants that underlie the
aggressive nature of de novo metastatic breast cancer.
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